

Sophia Karagiannis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4359258/publications.pdf>

Version: 2024-02-01

142
papers

5,220
citations

71102

41
h-index

102487

66
g-index

147
all docs

147
docs citations

147
times ranked

7821
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting folate receptor alpha for cancer treatment. <i>Oncotarget</i> , 2016, 7, 52553-52574.	1.8	308
2	Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. <i>Journal of Experimental Medicine</i> , 2012, 209, 935-945.	8.5	212
3	AllergoOncology: the role of IgE-mediated allergy in cancer. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1255-1266.	5.7	192
4	IgG4 subclass antibodies impair antitumor immunity in melanoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 1457-1474.	8.2	181
5	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	4.8	177
6	Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. <i>Nature Communications</i> , 2014, 5, 4255.	12.8	140
7	An Atlas of Human Regulatory T Helper-like Cells Reveals Features of Th2-like Tregs that Support a Tumorigenic Environment. <i>Cell Reports</i> , 2017, 20, 757-770.	6.4	118
8	IgE-Antibody-Dependent Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of Ovarian Cancer Cells. <i>Journal of Immunology</i> , 2007, 179, 2832-2843.	0.8	117
9	Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 915-930.	4.2	117
10	Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs). <i>Oncolimmunology</i> , 2018, 7, e1395127.	4.6	117
11	Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. <i>Cell</i> , 2019, 176, 757-774.e23.	28.9	117
12	Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. <i>European Journal of Immunology</i> , 2003, 33, 1030-1040.	2.9	106
13	TGF- β 2-Induced Transcription Sustains Amoeboid Melanoma Migration and Dissemination. <i>Current Biology</i> , 2015, 25, 2899-2914.	3.9	106
14	Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. <i>European Journal of Immunology</i> , 1999, 29, 3527-3537.	2.9	104
15	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 257-275.e6.	16.8	93
16	Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. <i>Cancer Cell</i> , 2020, 37, 85-103.e9.	16.8	91
17	Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types. <i>Frontiers in Immunology</i> , 2017, 8, 1911.	4.8	87
18	A tool kit for rapid cloning and expression of recombinant antibodies. <i>Scientific Reports</i> , 2014, 4, 5885.	3.3	85

#	ARTICLE	IF	CITATIONS
19	IgG4 Characteristics and Functions in Cancer Immunity. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 7.	5.3	76
20	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. <i>Oncotarget</i> , 2017, 8, 78174-78192.	1.8	75
21	Epidemiological associations of allergy, IgE and cancer. <i>Clinical and Experimental Allergy</i> , 2013, 43, 1110-1123.	2.9	73
22	Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2769-2783.	4.1	73
23	Revisiting the role of B cells in skin immune surveillance. <i>Trends in Immunology</i> , 2015, 36, 102-111.	6.8	73
24	Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies. <i>PLoS ONE</i> , 2011, 6, e19330.	2.5	72
25	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	2.9	71
26	AllergoOncology – the impact of allergy in oncology: EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 866-887.	5.7	68
27	Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. <i>Cancer Immunology, Immunotherapy</i> , 2007, 57, 247-263.	4.2	65
28	Anti-Folate Receptor Alpha – Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5098-5111.	7.0	65
29	IgE Antibodies: From Structure to Function and Clinical Translation. <i>Antibodies</i> , 2019, 8, 19.	2.5	62
30	Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells. <i>Immunology</i> , 2001, 103, 319-331.	4.4	61
31	WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. <i>Nature Communications</i> , 2020, 11, 5315.	12.8	59
32	Anti-Folate Receptor- α IgE but not IgG Recruits Macrophages to Attack Tumors via TNF α /MCP-1 Signaling. <i>Cancer Research</i> , 2017, 77, 1127-1141.	0.9	58
33	Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1547-1564.	4.2	55
34	AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 328-340.	5.7	54
35	Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. <i>Oncolimmunology</i> , 2015, 4, e1032492.	4.6	53
36	IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. <i>Scientific Reports</i> , 2016, 6, 29736.	3.3	52

#	ARTICLE	IF	CITATIONS
37	B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. <i>Oncolimmunology</i> , 2017, 6, e1294296.	4.6	51
38	Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort study. <i>Cancer Causes and Control</i> , 2010, 21, 1657-1667.	1.8	49
39	IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. <i>EBioMedicine</i> , 2019, 43, 67-81.	6.1	49
40	IgE immunotherapy. <i>MAbs</i> , 2014, 6, 54-72.	5.2	46
41	Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. <i>Journal of Immunological Methods</i> , 2007, 323, 160-171.	1.4	45
42	A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. <i>MAbs</i> , 2014, 6, 755-763.	5.2	44
43	Therapeutic IgE Antibodies: Harnessing a Macrophage-Mediated Immune Surveillance Mechanism against Cancer. <i>Cancer Research</i> , 2017, 77, 2779-2783.	0.9	42
44	Tumour-associated macrophage polarisation and re-education with immunotherapy. <i>Frontiers in Bioscience - Elite</i> , 2015, 7, 334-351.	1.8	41
45	AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer – a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Clinical and Translational Allergy</i> , 2020, 10, 32.	3.2	40
46	Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2021, 81, 4290-4304.	0.9	40
47	Beta-glucan contamination of pharmaceutical products: How much should we accept?. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1289-1301.	4.2	39
48	B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 622442.	4.8	39
49	Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of Fc ϵ R1-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. <i>Clinical and Experimental Allergy</i> , 2011, 41, 1400-1413.	2.9	38
50	Evaluating biomarkers in melanoma. <i>Frontiers in Oncology</i> , 2014, 4, 383.	2.8	38
51	Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). <i>Oncology Reports</i> , 2014, 32, 875-886.	2.6	37
52	The Role of IgG4 in the Fine Tuning of Tolerance in IgE-Mediated Allergy and Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5017.	4.1	36
53	Investigating the association between allergen-specific immunoglobulin E, cancer risk and survival. <i>Oncolimmunology</i> , 2016, 5, e1154250.	4.6	34
54	Mechanisms of checkpoint inhibition-induced adverse events. <i>Clinical and Experimental Immunology</i> , 2020, 200, 141-154.	2.6	33

#	ARTICLE	IF	CITATIONS
55	Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. <i>BMC Cancer</i> , 2019, 19, 858.	2.6	30
56	Near infrared photoimmunotherapy targeting bladder cancer with a canine anti-epidermal growth factor receptor (EGFR) antibody. <i>Oncotarget</i> , 2018, 9, 19026-19038.	1.8	30
57	IgG4 antibodies and cancer-associated inflammation. <i>Oncolimmunology</i> , 2013, 2, e24889.	4.6	28
58	AllergoOncology: IgE- and IgG 4 -mediated immune mechanisms linking allergy with cancer and their translational implications. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 982-984.	2.9	26
59	Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. <i>Cells</i> , 2020, 9, 1631.	4.1	26
60	Î±-Melanocyte-stimulating hormone: a protective peptide against chemotherapy-induced hair follicle damage?. <i>British Journal of Dermatology</i> , 2014, 170, 956-960.	1.5	25
61	Colocalisation of insulin and IGF-1 receptors in cultured rat sensory and sympathetic ganglion cells. <i>Journal of Anatomy</i> , 1997, 191, 431-440.	1.5	24
62	An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2328-2341.	5.7	24
63	Utilizing Immunocytokines for Cancer Therapy. <i>Antibodies</i> , 2021, 10, 10.	2.5	24
64	A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma. <i>Cancers</i> , 2020, 12, 1029.	3.7	22
65	Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. <i>Oncolimmunology</i> , 2019, 8, e1593811.	4.6	20
66	Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1519-1523.e9.	2.9	19
67	In Planta Glycan Engineering and Functional Activities of IgE Antibodies. <i>Frontiers in Bioengineering and Biotechnology</i> , 2019, 7, 242.	4.1	19
68	Dysregulated Antibody, Natural Killer Cell and Immune Mediator Profiles in Autoimmune Thyroid Diseases. <i>Cells</i> , 2020, 9, 665.	4.1	18
69	IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. <i>Oncolimmunology</i> , 2021, 10, 1880687.	4.6	18
70	Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. <i>Frontiers in Immunology</i> , 2017, 8, 1112.	4.8	17
71	AllergoOncology: Microbiota in allergy and cancer – A European Academy for Allergy and Clinical Immunology position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1037-1051.	5.7	17
72	IgE Antibodies against Cancer: Efficacy and Safety. <i>Antibodies</i> , 2020, 9, 55.	2.5	17

#	ARTICLE	IF	CITATIONS
73	Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer. <i>Trends in Molecular Medicine</i> , 2020, 26, 615-626.	6.7	17
74	Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. <i>Nature Communications</i> , 2022, 13, .	12.8	17
75	Recombinant plant-derived human IgE glycoproteomics. <i>Journal of Proteomics</i> , 2017, 161, 81-87.	2.4	16
76	AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice. <i>World Allergy Organization Journal</i> , 2019, 12, 100044.	3.5	16
77	Therapeutic targets and new directions for antibodies developed for ovarian cancer. <i>MAbs</i> , 2016, 8, 1437-1455.	5.2	15
78	IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. <i>Cancers</i> , 2020, 12, 3376.	3.7	15
79	Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 748-758.	6.4	15
80	Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. <i>Cancers</i> , 2021, 13, 4460.	3.7	15
81	Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies. <i>Biotechnology Progress</i> , 2016, 32, 1494-1502.	2.6	14
82	Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells. <i>Frontiers in Immunology</i> , 2018, 9, 493.	4.8	14
83	AllergoOncology: Generating a canine anticancer IgE against the epidermal growth factor receptor. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 973-976.e11.	2.9	14
84	AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1985-1989.	5.7	14
85	Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2069-2073.	5.7	14
86	Clinical and Translational Significance of Basophils in Patients with Cancer. <i>Cells</i> , 2022, 11, 438.	4.1	14
87	Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 527-538.	2.5	13
88	Abstract CT141: Phase 1 trial of MOv18, a first-in-class IgE antibody therapy for cancer. <i>Cancer Research</i> , 2020, 80, CT141-CT141.	0.9	13
89	Antibodies as biomarkers for cancer risk: a systematic review. <i>Clinical and Experimental Immunology</i> , 2022, 209, 46-63.	2.6	13
90	Advances in the treatment of melanoma. <i>Clinical Medicine</i> , 2012, 12, 168-171.	1.9	12

#	ARTICLE	IF	CITATIONS
91	Comparative reactivity of human IgE to cynomolgus monkey and human effector cells and effects on IgE effector cell potency. <i>MABs</i> , 2014, 6, 509-522.	5.2	12
92	<i>In vivo</i> safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. <i>MABs</i> , 2020, 12, 1685349.	5.2	11
93	Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). <i>Scientific Reports</i> , 2020, 10, 8869.	3.3	11
94	Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. , 2021, 9, e002140.		10
95	Potential for monocyte recruitment by IgE immunotherapy for cancer in a rat model of tumour metastasis. <i>Lancet, The</i> , 2015, 385, S53.	13.7	9
96	Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors. <i>Antibodies</i> , 2021, 10, 44.	2.5	9
97	Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma. <i>Critical Reviews in Biomedical Engineering</i> , 2012, 40, 279-294.	0.9	8
98	Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician. <i>Cancers</i> , 2021, 13, 5625.	3.7	8
99	BRAF inhibitors and their immunological effects in malignant melanoma. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 347-362.	3.0	8
100	Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. <i>Frontiers in Oncology</i> , 2020, 10, 263.	2.8	7
101	Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. <i>BMC Immunology</i> , 2021, 22, 61.	2.2	7
102	Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. <i>Clinical and Experimental Immunology</i> , 2022, 209, 4-21.	2.6	7
103	IgE Interacts with Potent Effector Cells Against Tumors: ADCC and ADCP. , 2010, , 185-213.		6
104	Novel drug-target interactions via link prediction and network embedding. <i>BMC Bioinformatics</i> , 2022, 23, 121.	2.6	6
105	CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. <i>Cancers</i> , 2022, 14, 3361.	3.7	6
106	Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study. <i>Frontiers in Oncology</i> , 2019, 9, 1095.	2.8	5
107	Epinephrine drives human M2a allergic macrophages to a regulatory phenotype reducing mast cell degranulation in vitro. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2939-2942.	5.7	5
108	Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. , 2021, 9, e002673.		5

#	ARTICLE	IF	CITATIONS
109	AllergoOncology: Danger signals in allergology and oncology: AÂEuropean Academy of Allergy and Clinical Immunology (EAACI) Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2594-2617.	5.7	5
110	Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment. <i>Microbiology Spectrum</i> , 2013, 1, .	3.0	4
111	Atopy and prostate cancer: Is there a link between circulating levels of IgE and PSA in humans?. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1557-1562.	4.2	4
112	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. <i>Cancer Epidemiology</i> , 2019, 62, 101584.	1.9	4
113	Innate stimulation of B cells <i>ex vivo</i> enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. <i>Clinical and Experimental Immunology</i> , 2022, 207, 84-94.	2.6	4
114	Immune cellâ€antibody interactions in health and disease. <i>Clinical and Experimental Immunology</i> , 2022, 209, 1-3.	2.6	4
115	Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG1 and IgG4 against the Major Birch Pollen Allergen Bet v 1. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5693.	4.1	3
116	PIPEâ€cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1553-1556.	5.7	3
117	<i>In vivo</i> trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. <i>Oncolmmunology</i> , 2021, 10, 1966970.	4.6	2
118	B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge. <i>Journal of Investigative Dermatology</i> , 2022, 142, 726-731.e4.	0.7	2
119	Abstract B65: IgG4 subclass antibodies impair antitumor immunity in melanoma., 2013, , .		2
120	Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. , 1999, 29, 3527.		1
121	Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review. <i>BMJ Open</i> , 2021, 11, e046052.	1.9	1
122	Abstract LB-001: Development and evaluation of T-Zap: a novel antibody-drug conjugate for the treatment of Her2 positive breast cancer. , 2018, , .		1
123	Special Issue â€œAntibody Engineering for Cancer Immunotherapyâ€• <i>Antibodies</i> , 2022, 11, 29.	2.5	1
124	Immunotherapy for melanoma. <i>Expert Review of Dermatology</i> , 2012, 7, 51-68.	0.3	0
125	Tumour-associated macrophage polarisation and re-education with immunotherapy. <i>Frontiers in Bioscience - Elite</i> , 2015, 7, 334-351.	1.8	0
126	355 A human in vivo model of a cutaneous memory B cell immune response to skin antigen challenge. <i>Journal of Investigative Dermatology</i> , 2016, 136, S221.	0.7	0

#	ARTICLE	IF	CITATIONS
127	483 Alternative activation of cutaneous B cells and IgG antibody subclass polarisation in melanoma. Journal of Investigative Dermatology, 2016, 136, S243.	0.7	0
128	Fast generation of IgE, IgG1 and IgG4 by PIPE cloning sharing the same variable region to the major birch pollen allergen Bet v 1. Journal of Allergy and Clinical Immunology, 2019, 143, AB186.	2.9	0
129	Fast and efficient cloning of human IgE, IgG1 and IgG4 antibodies specific for beta-lactoglobulin from cow milk by Polymerase Incomplete Primer Extension (PIPE). Journal of Allergy and Clinical Immunology, 2019, 143, AB260.	2.9	0
130	Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples. , 2021, , 329-350.		0
131	Abstract 2524: Antibodies of the IgG and IgE classes against the melanoma-associated antigen HMW-MAA: Investigating a new therapeutic approach. , 2012, , .		0
132	Abstract B46: Immunotherapy of solid tumors with IgE antibodies: Paradigm of a novel concept towards clinical application.. , 2013, , .		0
133	Immunoglobulin E and Allergy: Antibodies in Immune Inflammation and Treatment. , 0, , 75-102.		0
134	Abstract 1324: A translational platform to design antibodies targeting triple negative breast cancer-specific antigens for cancer immunotherapy. , 2015, , .		0
135	Abstract 1459: Patient-derived xenograft models of breast cancer with human immune components. , 2015, , .		0
136	Abstract A089: The circulating memory B cell compartment of breast cancer patients is depleted in comparison with healthy volunteers. , 2016, , .		0
137	Abstract A009: IgG4: a new tool to predict the risk of disease progression in melanoma. , 2016, , .		0
138	Abstract A090: Exploring folate receptor β immunotherapy of breast carcinomas: Human monocytic cell-mediated killing triggered by IgG1 and IgE antibodies. , 2016, , .		0
139	Abstract A116: IgG antibody switching and clonal expansion in melanoma and normal skin microenvironments. , 2016, , .		0
140	Antibody Therapeutics for Ovarian Carcinoma and Translation to the Clinic. , 2018, , .		0
141	Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Frontiers in Oncology, 0, 9, .	2.8	0
142	Abstract A095: Discovering the immune profiles of a novel antifolate receptor alpha IgE antibody associated with monocyte-mediated antitumor functions. , 2019, , .		0